Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002100119-26-001243
Filing Date
2026-04-30
Accepted
2026-04-30 14:34:43
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5692
  Complete submission text file 0002100119-26-001243.txt   7514
Mailing Address 6000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 6000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 (650) 243-6300
VERACYTE, INC. (Subject) CIK: 0001384101 (see all company filings)

EIN.: 205455398 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-87868 | Film No.: 26923588
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)

Mailing Address 100 VANGUARD BLVD MALVERN PA 19355
Business Address 100 VANGUARD BLVD MALVERN PA 19355 610-669-6148
VANGUARD CAPITAL MANAGEMENT LLC (Filed by) CIK: 0002100119 (see all company filings)

EIN.: 392877419 | State of Incorp.: PA | Fiscal Year End: 1231
LEI: 529900ZEWTRLEJ6XE960
Type: SCHEDULE 13G